Croda International, the Snaith, East Yorkshire-based FTSE 100 speciality chemicals giant, told investors on Friday that it expects “the recent strong organic growth in its drug delivery platforms to continue (excluding Covid-19 lipid systems), supplemented by an exciting innovation pipeline which is expected to commercialise from 2025.”

Croda hosted an investor seminar on its Health Care business, a business unit within its Life Sciences sector.

“The event will focus on growth opportunities in the pharmaceutical market and Croda’s unique positioning as an innovator of delivery systems for complex biologic drugs,” said the East Yorkshire firm.

“Croda expects the recent strong organic growth in its drug delivery platforms to continue (excluding Covid-19 lipid systems), supplemented by an exciting innovation pipeline which is expected to commercialise from 2025.

“There will be no new price sensitive information communicated at the event.”

Croda CEO Steve Foots said: “Over the last twenty years, we have been steadily growing and investing in our Health Care business, accelerating this progress with the acquisitions of vaccine adjuvant and lipid system technologies.

“Today we are focused on robust, high growth and high value markets, uniquely positioned as the leading innovator of delivery systems for complex biologic drugs and vaccines.

“It is an exciting part of Croda with significant opportunities to drive future growth.”